| Original language | Undefined/Unknown |
|---|---|
| Pages (from-to) | 1204-1211 |
| Journal | Haematologica |
| Volume | 99 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 2014 |
Cite this
}
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. / Hughes, T.P.; Hochhaus, A; Kantarjian, H.M.; Cervantes, F.; Guilhot, F.; Niederwieser, D.; le Coutre, P.D.; Rosti, G.; Ossenkoppele, G.J.; Lobo, C.; Shibayama, H.; Fan, X.L.; Menssen, H.D.; Kemp, C.; Larson, R.A.; Saglio, G.
In: Haematologica, Vol. 99, No. 7, 2014, p. 1204-1211.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
AU - Hughes, T.P.
AU - Hochhaus, A
AU - Kantarjian, H.M.
AU - Cervantes, F.
AU - Guilhot, F.
AU - Niederwieser, D.
AU - le Coutre, P.D.
AU - Rosti, G.
AU - Ossenkoppele, G.J.
AU - Lobo, C.
AU - Shibayama, H.
AU - Fan, X.L.
AU - Menssen, H.D.
AU - Kemp, C.
AU - Larson, R.A.
AU - Saglio, G.
PY - 2014
Y1 - 2014
U2 - 10.3324/haematol.2013.091272
DO - 10.3324/haematol.2013.091272
M3 - Article
VL - 99
SP - 1204
EP - 1211
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 7
ER -